Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.58 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | METAP1 | P53582 | 3/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748825 | 0.90 | DRD2 (0.64) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL27393934 | 0.88 | DRD2 (0.51) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7271049 | 0.85 | CYP24A1 (0.56) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL630841 | 0.85 | ACHE (0.58) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3587277 | 0.84 | CYP24A1 (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL5753017 | 0.84 | CYP24A1 (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL22867686 | 0.84 | CYP24A1 (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL2440274 | 0.84 | CYP24A1 (0.56) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL1813880 | 0.83 | CYP24A1 (0.54) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7519184 | 0.83 | CYP24A1 (0.54) | DRD2HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | DRD2 3539/4885HTR2A 4750/4885HTR2C 4819/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | DRD2 3539/4885HTR2A 4750/4885HTR2C 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.